(Santa Clara, Calif., May 24, 2016) — Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, will be exhibiting at booth 5125 at the American Society of Clinical Oncology (ASCO) annual meeting, which will take place June 3-7 at McCormick Place in Chicago.
CrownBio will be demonstrating its OncoExpress technology platform, an innovative resource that allows users to access all the data from CrownBio’s oncology models, including tumor growth curves, response to standard of care, biomarker identification, gene expression and mutation analysis. OncoExpress is a unique and powerful tool that collates data from the company’s PDX, CDX, syngeneic, GEMM and MuPrime™ models.
“OncoExpress has a simple, user-friendly interface that helps our clients and partners to find useful data faster than ever before,” said Laurie Heilmann, senior vice president of global strategy, marketing and business development. “Our goal is to provide reliable, well-organized data in a simple and easy-to-use format to accelerate drug discovery programs everywhere.”
In addition to introducing OncoExpress, a team of scientists will be available in Chicago to discuss the needs of companies developing therapeutics to address global oncology challenges.
“As a preclinical solutions provider, our team is excited to present this groundbreaking technology and to continue our efforts in moving cancer care and research forward with each new discovery,” Heilmann said.
The ultimate goal of ASCO 2016 is to bring health care professionals and specialists of diverse backgrounds together to share exciting advances and impactful insights in data technology. As a leader in drug discovery services, CrownBio possesses a depth of expertise in oncology and metabolic disease that increases the speed and efficiency of progressing preclinical candidates, improving the quality of decision making in clinical trials globally.
For more information on OncoExpress and CrownBio’s commitment to improving clinical outcomes, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.